Gruppenfoto der Arbeitsgruppe Materials Synthetic Biology im INM; die Mitarbeitenden stehen gemeinsam in einem Innenbereich vor großen Fenstern

Materialorientierte Synthetische Biologie

Unsere Inspiration ist die Anpassungsfähigkeit von Organismen und den Materialien, aus denen sie aufgebaut sind, an wechselnde Umweltbedingungen. Pflanzen passen ihr Wachstum an die Lichtverhältnisse an, Bakterien entwickeln Resistenzen gegen Antibiotika oder Knochen werden durch Belastung stärker. Grundlage für diese Anpassungsfähigkeit ist eine faszinierende Signalverarbeitung der Organismen: Durch molekulare Sensoren werden Umweltbedingungen wahrgenommen, die Signale werden prozessiert und mit dem genetischen Programm des Organismus integriert, um am Ende eine passgenaue Reaktion auszulösen.

In unserer Forschung verwenden wir diese molekularen informationsverarbeitenden Mechanismen, um die Funktion und Eigenschaften von Zellen und Materialien gezielt zu steuern. Dies eröffnet neuartige Möglichkeiten in der grundladen- und anwendungsorientierten Forschung.

Mehr Informationen finden Sie auf unserer englischsprachigen Seite.

Prof. Dr. Wilfried Weber,
Prof. Dr. Wilfried Weber
Leiter Materialorientierte Synthetische Biologie
Telefon: +49 (0)681-9300-520
Mitarbeiter/innen
Telefon: +49 (0)681-9300-435
E-Mail: mario.arenasgarcia@leibniz-inm.de
Telefon: +49 (0)681-9300-445
E-Mail: anja.armbruster@leibniz-inm.de
Telefon: +49 (0)681-9300-450
E-Mail: miguel.banos@leibniz-inm.de
Telefon: +49 (0)681-9300-444
E-Mail: jan.becker@leibniz-inm.de
Telefon: +49 (0)681-9300-435
E-Mail: Marc.BlanchAsensio@leibniz-inm.de
Telefon: +49 (0)681-9300-108/251
E-Mail: guillaume.ehret@leibniz-inm.de
Telefon: +49 (0)681-9300-446
E-Mail: sophia.eich@leibniz-inm.de
Telefon: +49 (0)681-9300-449
E-Mail: linda.elberskirch@leibniz-inm.de
Telefon: +49 (0)681-9300-334
E-Mail: christine.faller@leibniz-inm.de
Telefon: +49 (0)681-9300-449
E-Mail: cendi.gomes@leibniz-inm.de
Telefon: +49 (0)681-9300-435
E-Mail: payman.goodarzi@leibniz-inm.de
Telefon: +49 (0)681-9300-108/251
E-Mail: ruiqi.guo@leibniz-inm.de
Telefon: +49 (0)681-9300-445
E-Mail: mahmudul.hasan@leibniz-inm.de
Telefon: +49 (0)681-9300-449
E-Mail: meret.kaliske@leibniz-inm.de
Telefon: +49 (0)681-9300-446
E-Mail: marc.kehrer@leibniz-inm.de
Telefon: +49 (0)681-9300-352
E-Mail: ali.khazem@leibniz-inm.de
Telefon: +49 (0)681-9300-405
E-Mail: silke.kiefer@leibniz-inm.de
Telefon: +49 (0)681-9300-440
E-Mail: Annette.Kraegeloh@leibniz-inm.de
Telefon: +49 (0)681-9300-395
E-Mail: letitia.leydet@leibniz-inm.de
Telefon: +49 (0)681-9300-441
E-Mail: stefan.lohse@leibniz-inm.de
Telefon: +49 (0)681-9300-447
E-Mail: hanna.mayer@leibniz-inm.de
Telefon: +49 (0)681-9300-446/447
E-Mail: asim.mohamed@leibniz-inm.de
Telefon: +49 (0)681-9300-395
E-Mail: Berina.Muhovic@leibniz-inm.de
Telefon: +49 (0)681-9300-450
E-Mail: geisler.munoz-guamuro@leibniz-inm.de
Telefon: +49 (0)681-9300-435
E-Mail: stepanka.nedvedova@leibniz-inm.de
E-Mail: ha.pham@leibniz-inm.de
Telefon: +49 (0)681-9300-108/251
E-Mail: sadaf.reihani@leibniz-inm.de
E-Mail: katja.safa@leibniz-inm.de
Telefon: +49 (0)681-9300-352
E-Mail: lisa.sold@leibniz-inm.de
Telefon: +49 (0)681-9300-108/251
E-Mail: aisiri.srinivasa@leibniz-inm.de
Telefon: +49 (0)681-9300-448/449
E-Mail: pierre.trehin@leibniz-inm.de
Telefon: +49 (0)681-9300-445
E-Mail: sili.sunil@leibniz-inm.de
Telefon: +49 (0)681-9300-448
E-Mail: veronika.vetyskova@leibniz-inm.de
Telefon: +49 (0)681-9300-444
E-Mail: anke.weiand@leibniz-inm.de
Telefon: +49 (0)681-9300-108/251
E-Mail: di.wu@leibniz-inm.de
Telefon: +49 (0)681-9300-395
E-Mail: anabel.zwick@leibniz-inm.de

Publikationen

2022
Multiplexed biosensor for point-of-care COVID-19 monitoring: CRISPR-powered unamplified RNA diagnostics and protein-based therapeutic drug management

Johnston, M. | Ceren Ates, H. | Glatz, R. T. | Mohsenin, H. | Schmachtenberg, R. | Göppert, N. | Huzly, D. | Urban, G. A. | Weber, Wilfried | Dincer, C.

DOI:

In late 2019 SARS-CoV-2 rapidly spread to become a global pandemic, therefore, measures to attenuate chains of infection, such as high-throughput screenings and isolation of carriers were taken. Prerequisite for a reasonable and democratic implementation of such measures, however, is the availability of sufficient testing opportunities (beyond reverse transcription PCR, the current gold standard). We, therefore, propose an electrochemical, microfluidic multiplexed polymer-based biosensor in combination with CRISPR/Cas-powered assays for low-cost and accessible point-of-care nucleic acid testing. In this study, we simultaneously screen for and identify SARS-CoV-2 infections (Omicron-variant) in clinical specimens (Sample-to-result time: ∼30 min), employing LbuCas13a, whilst bypassing reverse transcription as well as target amplification of the viral RNA (LODs of 2,000 and 7,520 copies/µl for the E and RdRP genes, respectively, and 50 copies/ml for combined targets), both of which are necessary for detection via PCR and other isothermal methods. In addition, we demonstrate the feasibility of combining synthetic biology-driven assays based on different classes of biomolecules, in this case protein-based ß-lactam antibiotic detection, on the same device. The programmability of the effector and multiplexing capacity (up to six analytes) of our platform, in combination with a miniaturized measurement setup, including a credit card sized near field communication (NFC) potentiostat and a microperistaltic pump, provide a promising on-site tool for identifying individuals infected with variants of concern and monitoring their disease progression alongside other potential biomarkers or medication clearance. © 2022 The Author(s)

DOI:

Materials Today ,
2022, 61 129-138.

The living interface between synthetic biology and biomaterial design

Liu, A. P. | Appel, E. A. | Ashby, P. D. | Baker, B. M. | Franco, E. | Gu, L. | Haynes, K. | Joshi, N. S. | Kloxin, A. M. | Kouwer, P. H. J. | Mittal, J. | Morsut, L. | Noireaux, V. | Parekh, S. | Schulman, R. | Tang, S. K. Y. | Valentine, M. T. | Vega, S. L. | Weber, Wilfried | Stephanopoulos, N. | Chaudhuri, O.

DOI:

Recent far-reaching advances in synthetic biology have yielded exciting tools for the creation of new materials. Conversely, advances in the fundamental understanding of soft-condensed matter, polymers and biomaterials offer new avenues to extend the reach of synthetic biology. The broad and exciting range of possible applications have substantial implications to address grand challenges in health, biotechnology and sustainability. Despite the potentially transformative impact that lies at the interface of synthetic biology and biomaterials, the two fields have, so far, progressed mostly separately. This Perspective provides a review of recent key advances in these two fields, and a roadmap for collaboration at the interface between the two communities. We highlight the near-term applications of this interface to the development of hierarchically structured biomaterials, from bioinspired building blocks to ‘living’ materials that sense and respond based on the reciprocal interactions between materials and embedded cells. © 2022, Springer Nature Limited.

DOI:

Nature Materials ,
2022, 21 (4), 390-397.

Novel lectin-based chimeric antigen receptors target Gb3-positive tumour cells

Meléndez, A. V. | Velasco Cárdenas, R. M. H. | Lagies, S. | Strietz, J. | Siukstaite, L. | Thomas, O. S. | Tomisch, J. | Weber, Wilfried | Kammerer, B. | Römer, W. | Minguet, S.

DOI:

The link between cancer and aberrant glycosylation has recently become evident. Glycans and their altered forms, known as tumour-associated carbohydrate antigens (TACAs), are diverse, complex and difficult to target therapeutically. Lectins are naturally occurring glycan-binding proteins that offer a unique opportunity to recognise TACAs. T cells expressing chimeric antigen receptors (CARs) have proven to be a successful immunotherapy against leukaemias, but so far have shown limited success in solid tumours. We developed a panel of lectin-CARs that recognise the glycosphingolipid globotriaosylceramide (Gb3), which is overexpressed in various cancers, such as Burkitt's lymphoma, colorectal, breast and pancreatic. We have selected the following lectins: Shiga toxin's B-subunit from Shigella dysenteriae, LecA from Pseudomonas aeruginosa, and the engineered lectin Mitsuba from Mytilus galloprovincialis as antigen-binding domains and fused them to a well-known second-generation CAR. The Gb3-binding lectin-CARs have demonstrated target-specific cytotoxicity against Burkitt's lymphoma-derived cell lines as well as solid tumour cells from colorectal and triple-negative breast cancer. Our findings reveal the big potential of lectin-based CARs as therapeutical applications to target Gb3 and other TACAs expressed in haematological malignancies and solid tumours. © 2022, The Author(s).

DOI:

Cellular and Molecular Life Sciences ,
2022, 79 (10),

OPEN ACCESS
Signal-processing and adaptive prototissue formation in metabolic DNA protocells

Samanta, A. | Hörner, M. | Liu, W. | Weber, Wilfried | Walther, A.

DOI:

The fundamental life-defining processes in living cells, such as replication, division, adaptation, and tissue formation, occur via intertwined metabolic reaction networks that process signals for downstream effects with high precision in a confined, crowded environment. Hence, it is crucial to understand and reenact some of these functions in wholly synthetic cell-like entities (protocells) to envision designing soft materials with life-like traits. Herein, we report on all-DNA protocells composed of a liquid DNA interior and a hydrogel-like shell, harboring a catalytically active DNAzyme, that converts DNA signals into functional metabolites that lead to downstream adaptation processes via site-selective strand displacement reactions. The downstream processes include intra-protocellular phenotype-like changes, prototissue formation via multivalent interactions, and chemical messenger communication between active sender and dormant receiver cell populations for sorted heteroprototissue formation. The approach integrates several tools of DNA-nanoscience in a synchronized way to mimic life-like behavior in artificial systems for future interactive materials. © 2022, The Author(s).

DOI:

Nature Communications ,
2022, 13 (1),

OPEN ACCESS
Reversible Shielding and Immobilization of Liposomes and Viral Vectors by Tailored Antibody-Ligand Interactions

Thomas, O. S. | Rebmann, B. | Tonn, M. | Schirmeister, I. C. | Wehrle, S. | Becker, J. | Zea Jimenez, G. J. | Hook, S. | Jäger, S. | Klenzendorf, M. | Laskowski, M. | Kaier, A. | Pütz, G. | Zurbriggen, M. D. | Weber, Wilfried | Hörner, M. | Wagner, H. J.

DOI:

Controlling the time and dose of nanoparticulate drug delivery by administration of small molecule drugs holds promise for efficient and safer therapies. This study describes a versatile approach of exploiting antibody-ligand interactions for the design of small molecule-responsive nanocarrier and nanocomposite systems. For this purpose, antibody fragments (scFvs) specific for two distinct small molecule ligands are designed. Subsequently, the surface of nanoparticles (liposomes or adeno-associated viral vectors, AAVs) is modified with these ligands, serving as anchor points for scFv binding. By modifying the scFvs with polymer tails, they can act as a non-covalently bound shielding layer, which is recruited to the anchor points on the nanoparticle surface and prevents interactions with cultured mammalian cells. Administration of an excess of the respective ligand triggers competitive displacement of the shielding layer from the nanoparticle surface and restores nanoparticle-cell interactions. The same principle is applied for developing hydrogel depots that can release integrated AAVs or liposomes in response to small molecule ligands. The liberated nanoparticles subsequently deliver their cargoes to cells. In summary, the utilization of different antibody-ligand interactions, different nanoparticles, and different release systems validates the versatility of the design concept described herein. © 2021 The Authors. Small published by Wiley-VCH GmbH

DOI:

Small ,
2022, 18 (6), 2105157.

OPEN ACCESS
A small and highly sensitive red/far-red optogenetic switch for applications in mammals

Zhou, Y. | Kong, D. | Wang, X. | Yu, G. | Wu, X. | Guan, N. | Weber, Wilfried | Ye, H.

DOI:

Optogenetic technologies have transformed our ability to precisely control biological processes in time and space. Yet, current eukaryotic optogenetic systems are limited by large or complex optogenetic modules, long illumination times, low tissue penetration or slow activation and deactivation kinetics. Here, we report a red/far-red light-mediated and miniaturized Δphytochrome A (ΔPhyA)-based photoswitch (REDMAP) system based on the plant photoreceptor PhyA, which rapidly binds the shuttle protein far-red elongated hypocotyl 1 (FHY1) under illumination with 660-nm light with dissociation occurring at 730 nm. We demonstrate multiple applications of REDMAP, including dynamic on/off control of the endogenous Ras/Erk mitogen-activated protein kinase (MAPK) cascade and control of epigenetic remodeling using a REDMAP-mediated CRISPR–nuclease-deactivated Cas9 (CRISPR–dCas9) (REDMAPcas) system in mice. We also demonstrate the utility of REDMAP tools for in vivo applications by activating the expression of transgenes delivered by adeno-associated viruses (AAVs) or incorporated into cells in microcapsules implanted into mice, rats and rabbits illuminated by light-emitting diodes (LEDs). Further, we controlled glucose homeostasis in type 1 diabetic (T1D) mice and rats using REDMAP to trigger insulin expression. REDMAP is a compact and sensitive tool for the precise spatiotemporal control of biological activities in animals with applications in basic biology and potentially therapy. © 2021, The Author(s), under exclusive licence to Springer Nature America, Inc.

DOI:

Nature Biotechnology ,
2022, 40 (2), 262-272.

2021
CRISPR-powered electrochemical microfluidic multiplexed biosensor for target amplification-free miRNA diagnostics

Bruch, R. | Johnston, M. | Kling, A. | Mattmüller, T. | Baaske, J. | Partel, S. | Madlener, S. | Weber, Wilfried | Urban, G. A. | Dincer, C.

DOI:

Recently the use of microRNAs (miRNAs) as biomarkers for a multitude of diseases has gained substantial significance for clinical as well as point-of-care diagnostics. Amongst other challenges, however, it holds the central requirement that the concentration of a given miRNA must be evaluated within the context of other factors in order to unambiguously diagnose one specific disease. In terms of the development of diagnostic methods and devices, this implies an inevitable demand for multiplexing in order to be able to gauge the abundance of several components of interest in a patient's sample in parallel. In this study, we design and implement different multiplexed versions of our electrochemical microfluidic biosensor by dividing its channel into subsections, creating four novel chip designs for the amplification-free and simultaneous quantification of up to eight miRNAs on the CRISPR-Biosensor X (‘X’ highlighting the multiplexing aspect of the device). We then use a one-step model assay followed by amperometric readout in combination with a 2-min-stop-flow-protocol to explore the fluidic and mechanical characteristics and limitations of the different versions of the device. The sensor showing the best performance, is subsequently used for the Cas13a-powered proof-of-concept measurement of two miRNAs (miRNA-19b and miRNA-20a) from the miRNA-17–92 cluster, which is dysregulated in the blood of pediatric medulloblastoma patients. Quantification of the latter, alongside simultaneous negative control measurements are accomplished on the same device. We thereby confirm the applicability of our platform to the challenge of amplification-free, parallel detection of multiple nucleic acids. © 2020 Elsevier B.V.

DOI:

Biosensors and Bioelectronics ,
2021, 177

OPEN ACCESS
Synthetic biology as driver for the biologization of materials sciences

Burgos-Morales, O. | Gueye, M. | Lacombe, L. | Nowak, C. | Schmachtenberg, R. | Hörner, M. | Jerez-Longres, C. | Mohsenin, H. | Wagner, H. J. | Weber, Wilfried

DOI:

Materials in nature have fascinating properties that serve as a continuous source of inspiration for materials scientists. Accordingly, bio-mimetic and bio-inspired approaches have yielded remarkable structural and functional materials for a plethora of applications. Despite these advances, many properties of natural materials remain challenging or yet impossible to incorporate into synthetic materials. Natural materials are produced by living cells, which sense and process environmental cues and conditions by means of signaling and genetic programs, thereby controlling the biosynthesis, remodeling, functionalization, or degradation of the natural material. In this context, synthetic biology offers unique opportunities in materials sciences by providing direct access to the rational engineering of how a cell senses and processes environmental information and translates them into the properties and functions of materials. Here, we identify and review two main directions by which synthetic biology can be harnessed to provide new impulses for the biologization of the materials sciences: first, the engineering of cells to produce precursors for the subsequent synthesis of materials. This includes materials that are otherwise produced from petrochemical resources, but also materials where the bio-produced substances contribute unique properties and functions not existing in traditional materials. Second, engineered living materials that are formed or assembled by cells or in which cells contribute specific functions while remaining an integral part of the living composite material. We finally provide a perspective of future scientific directions of this promising area of research and discuss science policy that would be required to support research and development in this field. © 2021 The Author(s)

DOI:

Materials Today Bio ,
2021, 11

The Rise of Molecular Optogenetics

Advanced Biology ,
2021, 5 (5),

Red light-controlled viral gene delivery with single-cell resolution

Hörner, M. | Weber, Wilfried

DOI:

Available methods for efficient gene transfer into user-selected or even single cells suffer from high invasiveness or the need for complicated equipment. Here, we present a technology for the light-guided transduction of native cell lines and primary cells by adeno-associated viral (AAV) vectors. We demonstrate the spatially resolved transduction of different cells with different genes within one culture and the selective transduction of single cells by local illumination. © 2021, Die Autoren.

DOI:

BioSpektrum ,
2021, 27 (6), 620-622.

OPEN ACCESS